Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

By afschroeder • October 8, 2025

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy. Front Oncol. 2025 Sep 22;15:1649493. doi: 10.3389/fonc.2025.1649493. PMID: 41059291; PMCID: PMC12497632.

Tags: antagonists, clinical efficacy, combination drug therapy, drug administration schedules, exportin 1, Hematology/Oncology, inhibitors, Multiple myeloma, Publications, selinexor

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim DM,[...]

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, Hu R, Tang C, Liu Q, Zeng W, Yeh A, Melehy A, Tran[...]

Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

López JCV, Ho A, Hughes KS, Bardia A, Vidula N. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to[...]